HOME >> BIOLOGY >> NEWS
Vaccine hope for sufferers of potentially fatal stomach bug

Scientists at The University of Nottingham have been awarded over 366,000 to help unravel the mystery of a stomach bug which causes gastric ulcers and cancer. Their research could lead to the development of a vaccine for those most at risk.

The bacterium, Helicobacter pylori (Hp), lives in the stomachs of approximately half the worlds population. Dr Karen Robinson, a lecturer at the Centre of Biomolecular Sciences and co-researcher John Atherton, Professor of Gastroenterology and Head of the Wolfson Digestive Diseases Centre, lead a team of scientists that have spent the last three years trying to discover why most people are immune to the bug while it can cause potentially fatal disease in some people.

Dr Robinson says this new funding, from the Medical Research Council, will allow them to address one of the most important questions in Helicobacter research why some infected individuals develop ulcers or gastric cancer whilst others remain asymptomatic. My interest is in the immune response and how this dictates whether or not an infected person goes on to develop disease.

In recent studies the team has shown that the bacteria induce changes to the immune system which calm the inflammation down. However, sometimes this relationship goes wrong. Their experiments showed that people with ulcers often have a suppressed protective response, leading to the development of severe inflammation and ulceration of the stomach lining.

If we become infected with Hp it generally happens in childhood. The bacteria can remain undetected in the stomach for life. However, in some people it causes inflammation which leads to gastric ulcers or cancer in later years. Scientists at The University of Nottingham believe the Hp manipulates the immune system and patients arent aware of a problem until the disease has become so advanced they need surgery or chemotherapy.

The occurrence of the disease is currently thought to be due to
'"/>

Contact: Karen Robinson
44-011-582-31094
University of Nottingham
26-Apr-2007


Page: 1 2

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine to cope with viral diversity in HIV
5. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
6. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
7. Vaccine-producing plant-factories
8. HPV Vaccine: Whats next
9. Vaccine shown effective against chancroid
10. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine hope for sufferers potentially fatal stomach bug

(Date:4/15/2014)... LIVERMORE, Calif. Zero-emission hydrogen fuel cell systems soon could ... industrial settings at lower costs and with faster refueling ... Sandia National Laboratories and Hawaii Hydrogen Carriers (HHC). , ... solid-state hydrogen storage system that can refuel at low ... to charge a battery-powered forklift, giving hydrogen a competitive ...
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... you,re over 24 years of age you,ve already reached ... according to a new Simon Fraser University study. ... professor Mark Blair, Thompson,s thesis supervisor, and Andrew Henrey, ... news in a just-published PLOS ONE Journal ... science experiments to rest on big data, the trio ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ... navigate and understand both the current standard of care ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... whether technology developed to win races on the Formula ... obesity.  This unique healthcare collaboration between McLaren Applied Technologies ... academics at University Campus Suffolk is being funded by ... inspired by equipment used to collect data about the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS ... enhancement to its Online Web Portal for Life Science ... have the ability to specify the subject matter of ... 50 life science sub-domains. This will help reduce time-to-delivery ... scientific fields, and decrease the likelihood of error. , ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: